Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

German HTA Blueprint Could Be Imposed On Greece

This article was originally published in The Pink Sheet Daily

Executive Summary

Germany’s role in preparing a health reform agreement between Greece and the World Health Organization may lead to a G-BA/IQWiG-style HTA process being introduced in the Hellenic Republic.

You may also be interested in...



European Notebook: Shake-Up At EMA, Restructuring At Pierre Fabre, Reinhardt Returns To Novartis

A new leadership team at EMA to be unveiled in September; the death of Pierre Fabre leads to management restructuring at France's third largest pharma; Reinhardt to review strategy as he replaces Vasella at the Swiss multinational, Novartis; and more…

Greece, Slashing Drug Budget Via Cuts And Non-Payment, Backs Generics

Greece has slashed its pharmaceutical budget in half by price cuts and withholding payments, but it is now turning to generics to fulfill its citizens’ health care needs.

German Pharma Industry Cries Foul As Preliminary Evaluation Of AMNOG Suggests It Works

Germany’s powerful health care watchdog G-BA, in its first full opinion on early added benefit assessment of medicines, says the process is fair and promotes real drug innovation, in sharp contrast to the biopharma industry which maintains it is a cost-cutting tool wielded by health insurance funds.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS076050

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel